United States · Platforms & data · TradingView
Johnson & Johnson looking to buy Ollin Biosciences for up to $3.4 billion, FT says

Detailed summary
Johnson & Johnson NYSE:JNJ is poised to buy privately held eye disease drug developer Ollin Biosciences for up to $3.4 billion, the Financial Times reported on Sunday, citing people familiar with the matter.Under the terms of the deal being discussed, J&J could pay Ollin’s backers $2.2 billion upfr…
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.tradingview.com)




